Earnings summaries and quarterly performance for Anebulo Pharmaceuticals.
Executive leadership at Anebulo Pharmaceuticals.
Board of directors at Anebulo Pharmaceuticals.
Research analysts covering Anebulo Pharmaceuticals.
Recent press releases and 8-K filings for ANEB.
Anebulo Pharmaceuticals Announces Voluntary Delisting from Nasdaq
ANEB
Delisting/Listing Issues
- Anebulo Pharmaceuticals announced its intention to voluntarily delist its common stock from The Nasdaq Capital Market and deregister with the SEC.
- The company plans to file a Form 25 with the SEC on or about February 17, 2026, with the delisting from Nasdaq expected to become effective on February 27, 2026.
- The Board's decision was based on the belief that the costs of being an SEC reporting company outweigh the benefits, despite the company being in compliance with applicable Nasdaq listing requirements.
- Following the delisting, any trading in Anebulo’s common stock would only occur in privately negotiated sales and potentially on the over-the-counter market.
21 hours ago
Anebulo Pharmaceuticals Announces Voluntary Delisting from Nasdaq
ANEB
Delisting/Listing Issues
- Anebulo Pharmaceuticals, Inc. (ANEB) announced its decision to voluntarily delist its common stock from The Nasdaq Capital Market and deregister with the SEC.
- The company plans to file a Form 25 with the SEC on or about February 17, 2026, with the delisting from Nasdaq expected to become effective on February 27, 2026.
- Anebulo intends to file a Form 15 on or about February 27, 2026, which will immediately suspend its SEC periodic reporting obligations upon filing.
- The Board determined that the costs of operating as a registered public company outweigh the advantages, despite the company being in compliance with Nasdaq listing requirements.
21 hours ago
Anebulo Pharmaceuticals Plans Self-Tender to Go Private
ANEB
Share Buyback
Delisting/Listing Issues
- Anebulo Pharmaceuticals has abandoned its previously proposed large reverse stock split and will instead launch a voluntary cash tender offer.
- The company plans to buy up to 300,000 shares at $3.50 per share, totaling up to $1.05 million, as part of its strategy to go private.
- This tender offer aims to reduce the shareholder count below the 300-shareholder threshold required for delisting and deregistration, as the reverse split became too costly due to fractional-share payout expenses.
Dec 22, 2025, 2:14 PM
Anebulo Pharmaceuticals Announces Intent to Commence Self Tender Offer for Go-Private Transaction
ANEB
Share Buyback
Delisting/Listing Issues
- Anebulo Pharmaceuticals, Inc. (ANEB) announced its intent to commence a cash tender offer to acquire up to 300,000 shares of its common stock at $3.50 per share, for an aggregate purchase price of up to $1,050,000.
- This tender offer is part of the company's plan to "go private" and is being undertaken in lieu of a previously announced reverse stock split.
- The Board of Directors decided to abandon the reverse stock split because its costs, primarily due to an increase in shares held in multiple small accounts, now outweigh the benefits.
- The tender offer aims to help the company maintain its number of stockholders at below 300, which is necessary for its "go private" transaction.
Dec 22, 2025, 2:00 PM
Anebulo Pharmaceuticals Reports Q1 Fiscal Year 2026 Results and Business Updates
ANEB
Earnings
New Projects/Investments
M&A
- Anebulo Pharmaceuticals reported a net loss of $2.2 million, or $(0.05) per share, for the first quarter of fiscal year 2026, which ended September 30, 2025.
- As of September 30, 2025, the company had $10.4 million in cash and cash equivalents, with access to an additional $3.0 million through a Loan Agreement.
- On September 25, 2025, Anebulo announced the dosing of the first subjects in a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of selonabant for acute cannabis-induced toxicity in children. This study is supported by a $994,300 grant from the National Institute on Drug Abuse (NIDA).
- The Board is reviewing strategic alternatives, including a proposed reverse stock split as part of a going private transaction, with a further announcement expected by the end of the year.
Nov 13, 2025, 9:15 PM
Anebulo Pharmaceuticals Reports Q4 and FY 2025 Results, Initiates Clinical Study, and Proposes Reverse Stock Split
ANEB
Earnings
New Projects/Investments
Delisting/Listing Issues
- Anebulo Pharmaceuticals reported a net loss of $2.1 million, or $(0.05) per share, for the fourth quarter of fiscal year 2025, and a net loss of $8.5 million, or $(0.25) per share, for the full fiscal year 2025.
- As of June 30, 2025, the company had $11.6 million in cash and cash equivalents.
- On September 25, 2025, Anebulo initiated a Phase 1 single ascending dose (SAD) study for an intravenous (IV) formulation of its lead drug candidate, selonabant, for acute cannabis-induced toxicity in children, supported by a $994,300 grant from the National Institute on Drug Abuse (NIDA).
- The Board of Directors has approved a proposed reverse stock split, subject to stockholder approval, as part of a going private transaction intended to maintain fewer than 300 record holders and avoid SEC public reporting requirements.
Sep 29, 2025, 8:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more